ROR1: an orphan becomes apparent
TJ Kipps - Blood, The Journal of the American Society of …, 2022 - ashpublications.org
Since its initial identification in 1992 as a possible class 1 cell-surface receptor without a
known parent ligand, receptor tyrosine kinase–like orphan receptor 1 (ROR1) has stimulated …
known parent ligand, receptor tyrosine kinase–like orphan receptor 1 (ROR1) has stimulated …
The WNT/ROR pathway in cancer: from signaling to therapeutic intervention
K Menck, S Heinrichs, C Baden, A Bleckmann - Cells, 2021 - mdpi.com
The WNT pathway is one of the major signaling cascades frequently deregulated in human
cancer. While research had initially focused on signal transduction centered on β-catenin as …
cancer. While research had initially focused on signal transduction centered on β-catenin as …
A ROR1–HER3–lncRNA signalling axis modulates the Hippo–YAP pathway to regulate bone metastasis
Bone metastases remain a serious health concern because of limited therapeutic options.
Here, we report that crosstalk between ROR1–HER3 and the Hippo–YAP pathway promotes …
Here, we report that crosstalk between ROR1–HER3 and the Hippo–YAP pathway promotes …
Zilovertamab vedotin targeting of ROR1 as therapy for lymphoid cancers
Background Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is an oncofetal protein
present on many cancers. Zilovertamab vedotin (ZV) is an antibody–drug conjugate …
present on many cancers. Zilovertamab vedotin (ZV) is an antibody–drug conjugate …
Small-molecule inhibitors of the receptor tyrosine kinases: promising tools for targeted cancer therapies
M Hojjat-Farsangi - International journal of molecular sciences, 2014 - mdpi.com
Chemotherapeutic and cytotoxic drugs are widely used in the treatment of cancer. In spite of
the improvements in the life quality of patients, their effectiveness is compromised by several …
the improvements in the life quality of patients, their effectiveness is compromised by several …
ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient–derived xenograft mouse models
T Vaisitti, F Arruga, N Vitale, TT Lee… - Blood, The Journal …, 2021 - ashpublications.org
Richter syndrome (RS) represents the transformation of chronic lymphocytic leukemia (CLL),
typically to an aggressive lymphoma. Treatment options for RS are limited and the disease is …
typically to an aggressive lymphoma. Treatment options for RS are limited and the disease is …
High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia
ROR1 is an oncoembryonic orphan receptor found on chronic lymphocytic leukemia (CLL) B
cells, but not on normal postpartum tissues. ROR1 is a receptor for Wnt5a that may complex …
cells, but not on normal postpartum tissues. ROR1 is a receptor for Wnt5a that may complex …
Targeting casein kinase 1 (CK1) in hematological cancers
P Janovská, E Normant, H Miskin, V Bryja - International Journal of …, 2020 - mdpi.com
The casein kinase 1 enzymes (CK1) form a family of serine/threonine kinases with seven
CK1 isoforms identified in humans. The most important substrates of CK1 kinases are …
CK1 isoforms identified in humans. The most important substrates of CK1 kinases are …
Relapsed/refractory diffuse large B-cell lymphoma: a look at the approved and emerging therapies
Y Sawalha - Journal of Personalized Medicine, 2021 - mdpi.com
Approximately 40% of patients with diffuse large B cell lymphoma (DLBCL) do not respond
or develop relapsed disease after first-line chemoimmunotherapy. A minority of these …
or develop relapsed disease after first-line chemoimmunotherapy. A minority of these …
ROR1, an embryonic protein with an emerging role in cancer biology
Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is a member of the ROR family
consisting of ROR1 and ROR2. RORs contain two distinct extracellular cysteine-rich …
consisting of ROR1 and ROR2. RORs contain two distinct extracellular cysteine-rich …